• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Tobacco Endgame: 4 Major Cardiology Societies Press World Governments to Act

Article

Slide Show

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

The American Heart Association, American College of Cardiology, European Society of Cardiology and World Heart Federation on May 26 released a joint opinion focused on realizing the "tobacco endgame." The opinion, The Tobacco Endgame—Eradicating a Worsening Epidemic, published in the journal Circulation, calls for a significant increase in action on a global scale toward permanent eradication of tobacco use.

The joint opinion partners urge governments worldwide to put into practice the World Health Organization's (WHO) MPOWER framework which outlines 6 essential policy approaches proven to reduce tobacco use. Progress will require countries to fund comprehensive tobacco prevention strategies.

The following slides summarize the opinion, including the global impact of tobacco use, the MPOWER calls to action, the joint partners' support, and specific calls to governments worldwide.


Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.